Exelixis (EXEL)
(Delayed Data from NSDQ)
$27.60 USD
+0.13 (0.47%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $27.64 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum B VGM
Price, Consensus and EPS Surprise
EXEL 27.60 +0.13(0.47%)
Will EXEL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXEL
Here's Why Exelixis (EXEL) is a Strong Value Stock
Here's Why Exelixis (EXEL) is a Strong Value Stock
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
Other News for EXEL
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Exelixis announces final results from CABINET study
Exelixis (EXEL) Gets a Hold from Stifel Nicolaus
Buy Rating on Exelixis: Optimism Fueled by Cabozantinib’s Trial Success and Near-Term Catalysts
IHF: Healthcare Dashboard For September